The company said its earnings before interest, taxes, depreciation and amortisation (Ebitda) stood at RM233.3 million, representing an 11% increase and an Ebitda margin of 22.2%.
Its profit after tax, zakat and minority interest (Patami) rose 22% y-o-y to RM69.6 million with a Patami margin of 6.6%, thanks to greater revenue intensity, disciplined cost management and the company’s system integration.
The company saw inpatient admissions grow 2% to 88,863 in Q1, while outpatient visits went up by 1% to 695,332 and surgeries rose 2% to 27,565.
“Average revenue per inpatient went up 6% and average revenue per outpatient increased by 7%, supported by improved case mix and sustained demand for more complex treatments and specialised services,” it added.
The company declared an interim dividend of one sen per share, totalling RM44.3 million, which will be paid out on July 17.
KPJ Healthcare president and managing director Chin Keat Chyuan said this marked a strong start to the financial year with the company seeing healthy revenue growth, greater earnings and higher revenue intensity.
In a statement, Chin said these were the early returns of KPJ Healthcare’s shift towards system-led value creation.
“More significant than the quarterly performance is the structural repositioning of the group under our 2026–2030 Strategic Plan and the KPJ Health System.
“Importantly, the strength of KPJ Healthcare lies in the institution, capabilities and integrated system being built across the group. This is what will sustain earnings quality, lift system-wide efficiency and create durable shareholder value over the long term,” he said.
In the second quarter of 2026, KPJ Healthcare is recalibrating its entire business ecosystem to ensure full alignment with the KPJ Health System’s objectives.
It will continue to advance the system’s transformation agenda company-wide, with a focus on converging artificial intelligence with genomics and value-based care.
The company has also started developing a new health information system and will continue its targeted recruitment efforts for top clinical, research and innovation talent.
It expects the external business environment to remain fluid amid geopolitical instability, but this has not caused any direct impact on the company so far.
“We will continue to monitor developments closely and take mitigating actions where necessary,” it said.